Patent · US Active

Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)

US9295713B2 · kind B2 · utility

1Cited by

8References

19Claims

0Family size

Assignees

Celldex Therapeutics, Inc. · US
University of Iowa Research Foundation · US

Inventors

Richard J. H. Smith · Brisbane, US
Yuzhou Zhang · Lo Wu, CN
Henry C. Marsh, Jr. · Reading, US

Key dates

Filing date	Sep 15, 2011
Grant date	Mar 29, 2016
Priority date	—
Expiry date	Jun 15, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.